Avalo Therapeutics Inc (AVTX) Stock Price, Quote & News

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and i...

Industry: Biotechnology

Sector: Healthcare

Phone: 410 522 8707

Website: www.avalotx.com

Address:

540 Gaither Road, Suite 400, Rockville, United States

HedgeAlerts Nov. 15 at 11:12 PM

Hedge Alert Live - Protect Your Portfolio Contract: $AVTX $15.00 Put · NOV 21, 2025 Exp Entry Price: $1.00 - $4.90 Exit Price Target: $1.94 Profit Margin: +94% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

MoneyGroupLLC Nov. 15 at 10:38 AM

Enter: $AVTX Calls Strike Price: $20 Expiry Date: DEC 19 2025 Buy in Price: $3.00 - $4.90 Sell Price: $6.54 Profit : +118% (Turn every $1 into $2.18) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

HedgeAlerts Nov. 14 at 6:55 PM

Hedge Alert Live - Protect Your Portfolio Contract: $AVTX $12.50 Put · NOV 21, 2025 Exp Entry Price: $0.45 - $0.45 Exit Price Target: $0.83 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Trapjaw Nov. 14 at 5:50 PM

$AVTX

0 · Reply

Steve_TheBull_Rogers Nov. 14 at 11:54 AM

$AVTX IMO chmp does not even mention avxl so I cite a withdrawl or delay for them Locked in nearly all gains. Will be back in DEC Been fun longs, See you in Dec

1 · Reply

Steve_TheBull_Rogers Nov. 14 at 11:50 AM

$AVTX Covered rest of my short here now at 5.20 No point holding it for another month Locking in 10k profit on it fully out short. Will re-enter nearer Dec and roll the 32 $4 Put contracts I have left Followers if short stock just cover here at low 5s no point holding it for another month of range trading. This will not channel trade until Dec

0 · Reply

HedgeAlerts Nov. 14 at 8:14 AM

Hedge Alert Live - Protect Your Portfolio Contract: $AVTX $12.50 Put · NOV 21, 2025 Exp Entry Price: $0.45 - $0.55 Exit Price Target: $0.77 Profit Margin: +70% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

BubbleBoyLippmann Nov. 13 at 7:18 PM

$SRPT $NVO Is it the spring of healthcare sector finally? $IFRX $MLTX $AVTX

0 · Reply

Redbet69 Nov. 13 at 4:19 PM

$AVTX Anyone here ?

0 · Reply

MoneyGroupLLC Nov. 13 at 12:38 PM

Enter: $AVTX Calls Strike Price: $20 Expiry Date: DEC 19 2025 Buy in Price: $3.00 - $4.90 Sell Price: $4.23 Profit : +41% (Turn every $1 into $1.41) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 3, 2025, 7:00 AM EST - 12 days ago

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Oct 29, 2025, 7:00 AM EDT - 17 days ago

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 1, 2025, 7:00 AM EDT - 6 weeks ago

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Sep 22, 2025, 7:00 AM EDT - 7 weeks ago

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Aug 18, 2025, 8:30 AM EDT - 3 months ago

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results

Aug 7, 2025, 7:00 AM EDT - 3 months ago

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Jun 18, 2025, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

May 12, 2025, 7:00 AM EDT - 6 months ago

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 30, 2025, 7:00 AM EDT - 7 months ago

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Mar 26, 2025, 7:00 AM EDT - 8 months ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mar 25, 2025, 3:20 PM EDT - 8 months ago

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Mar 20, 2025, 7:00 AM EDT - 8 months ago

Avalo Reports 2024 Financial Results and Recent Business Updates

Feb 4, 2025, 8:00 AM EST - 10 months ago

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 2, 2025, 7:00 AM EST - 11 months ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Nov 12, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 11, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jun 24, 2024, 4:01 PM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 17, 2024, 7:30 AM EDT - 1 year ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

May 13, 2024, 7:30 AM EDT - 1 year ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 1, 2024, 6:02 AM EDT - 1 year ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Mar 29, 2024, 4:01 PM EDT - 1 year ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Dec 27, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Nov 9, 2023, 7:00 AM EST - 2 years ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Avalo Completes Divestiture of AVTX-800 Series

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 2:10 AM EDT - 2 years ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jul 6, 2023, 4:01 PM EDT - 2 years ago

Avalo to Participate in SVB Securities Therapeutics Forum

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the Jefferies Healthcare Conference

May 22, 2023, 7:00 AM EDT - 2 years ago

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

May 15, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 10, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 4, 2023, 4:01 PM EDT - 2 years ago

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Mar 29, 2023, 7:30 AM EDT - 2 years ago

Avalo Reports 2022 Financial Results and Provides Business Updates

Mar 7, 2023, 7:00 AM EST - 2 years ago

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Feb 2, 2023, 9:54 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Feb 2, 2023, 4:01 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Jan 17, 2023, 7:00 AM EST - 3 years ago

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Nov 7, 2022, 7:30 AM EST - 3 years ago

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

HedgeAlerts Nov. 15 at 11:12 PM

0 · Reply

MoneyGroupLLC Nov. 15 at 10:38 AM

0 · Reply

HedgeAlerts Nov. 14 at 6:55 PM

0 · Reply

Trapjaw Nov. 14 at 5:50 PM

$AVTX

0 · Reply

Steve_TheBull_Rogers Nov. 14 at 11:54 AM

$AVTX IMO chmp does not even mention avxl so I cite a withdrawl or delay for them Locked in nearly all gains. Will be back in DEC Been fun longs, See you in Dec

1 · Reply

Steve_TheBull_Rogers Nov. 14 at 11:50 AM

0 · Reply

HedgeAlerts Nov. 14 at 8:14 AM

0 · Reply

BubbleBoyLippmann Nov. 13 at 7:18 PM

$SRPT $NVO Is it the spring of healthcare sector finally? $IFRX $MLTX $AVTX

0 · Reply

Redbet69 Nov. 13 at 4:19 PM

$AVTX Anyone here ?

0 · Reply

MoneyGroupLLC Nov. 13 at 12:38 PM

0 · Reply

MoneyGroupLLC Nov. 12 at 12:27 PM

Enter: $AVTX Calls Strike Price: $20 Expiry Date: DEC 19 2025 Buy in Price: $3.00 - $4.90 Sell Price: $6.06 Profit : +102% (Turn every $1 into $2.02) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Iightning Nov. 10 at 5:17 AM

1ightning® Options Trade Alert (Actionable) | Buy $AVTX Nov 21 $20 Call | Enter: $3.65 Exit: $4.46 | Profit: 22.30% ROI | https://1ightning.com

0 · Reply

LiquidThetaOptions Nov. 9 at 12:02 PM

💎 LiquidTheta® Live Actionable Trade Asset: $AVTX Contracts: $AVTX June 18, 2026 $20 Calls Scale in: $6.35- $7.76 Scale out: $24.68-$42.30 Profit Potential : 381% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Masonic11 Nov. 9 at 1:56 AM

$AVTX Thats Aevi Genomic's drug and these pos theives sat on it, blaming covid on it. They drugg their heals on it. I believe that fukn trash ass pos Neil purposely shit all over us CVR AEVI share holders. I never trusted the guy! Look back, when it was Cerecor. How was his track record then???? Yes, I'm pissed. I invested in a company that is the only reason that this one exists. Dirty Robinhood too, all crooks.

0 · Reply

MoneyGroupLLC Nov. 8 at 12:39 PM

Enter: $AVTX Calls Strike Price: $20 Expiry Date: DEC 19 2025 Buy in Price: $3.00 - $4.40 Sell Price: $5.61 Profit : +87% (Turn every $1 into $1.87) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Trapjaw Nov. 7 at 3:21 PM

$AVTX

0 · Reply

MoneyGroupLLC Nov. 7 at 11:03 AM

Enter: $AVTX Calls Strike Price: $20 Expiry Date: DEC 19 2025 Buy in Price: $3.00 - $4.90 Sell Price: $6.09 Profit : +103% (Turn every $1 into $2.03) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Iightning Nov. 7 at 3:53 AM

1ightning® Options Trade Alert (Actionable) | Buy $AVTX Nov 21 $20 Call | Enter: $3.65 Exit: $4.46 | Profit: 22.30% ROI | https://1ightning.com

0 · Reply

Trapjaw Nov. 5 at 3:47 PM

$AVTX

1 · Reply

Trapjaw Nov. 5 at 2:36 PM

$AVTX https://finviz.com/news/209518/piper-sandler-maintains-bullish-48-price-target-on-avalo-therapeutics-avtx

0 · Reply

Trapjaw Nov. 3 at 12:39 PM

$AVTX https://ir.avalotx.com/news-events-presentations/press-releases/detail/212/avalo-therapeutics-to-participate-in-upcoming-investor-conferences

0 · Reply

MoneyGroupLLC Nov. 3 at 8:47 AM

Enter: $AVTX Calls Strike Price: $20 Expiry Date: DEC 19 2025 Buy in Price: $3.00 - $4.90 Sell Price: $4.71 Profit : +57% (Turn every $1 into $1.57) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Market Cap	274.01M
Revenue (ttm)	440,000.00
Net Income (ttm)	-35.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,984.09%
Debt to Equity Ratio	0.00

Volume	526,900
Avg Vol	402,330
Day's Range	N/A - N/A
Shares Out	18.13M
Stochastic %K	35%
Beta	0.94
Analysts	Strong Sell
Price Target	$35.33